Ionis' Tryngolza becomes EU's first RNA therapy for severe high triglycerides
The European Commission cleared Ionis' Tryngolza (olezarsen) for adults with severe hypertriglyceridemia and fasting triglycerides of at least 880 mg/dL, making it the first RNA-targeted therapy approved for that group in the EU. The win follows a positive CHMP opinion in October 2026, but it lands as US sales of the drug badly miss expectations and Ionis' stock sinks 65.9% this year.
- Original source: finance.yahoo.com.
- The source published it on Nov 18, 2026 at 8:34 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The European Commission has signed off on Tryngolza for adults with severe hypertriglyceridemia whose fasting triglyceride levels hit at least 880 mg/dL. Patients will take the olezarsen-based drug alongside diet and other lipid-lowering therapies. It is the first RNA-targeted therapy cleared in the European Union for this patient population.
The green light was no surprise. The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval back in October 2026, and Ionis already held an EU nod for familial chylomicronemia syndrome from 2025. This decision stretches the label to a much wider group. The FDA had cleared Tryngolza for sHTG in the US in June 2026.
The European filing leaned on the phase III CORE and CORE2 trials, which both hit their primary endpoints with significant drops in fasting triglycerides versus placebo. The studies also showed fewer acute pancreatitis events and a favorable safety and tolerability profile. That matters because triglycerides at or above 880 mg/dL carry a higher risk of acute pancreatitis, a life-threatening condition that can bring severe abdominal pain, long hospital stays and permanent organ damage. For context, sHTG itself starts at 500 mg/dL.
Sobi holds exclusive commercialization rights to Tryngolza outside the United States, Canada and China, so the EU expansion widens the drug's reach without Ionis building its own European sales force. Ionis sells it directly in the US, where it is the company's first wholly owned commercial product, first approved by the FDA for FCS in December 2024.
The commercial picture is grimmer than the regulatory one. Tryngolza posted $41 million in net product sales over the first nine months of 2026, down 28.5% year over year, and roughly $9 million in the third quarter alone, missing the Zacks Consensus Estimate of $23.1 million. Management blamed a slower-than-expected launch ramp, with physicians taking time to adopt the treatment and reimbursement coverage filling in gradually. Ionis cut its full-year 2026 Tryngolza sales guidance from $100-$110 million to about $50 million. Shares of IONS have fallen 65.9% so far this year, against a 1.8% drop for the industry.
TopicsIonis Pharmaceuticals · Tryngolza · olezarsen · European Commission · Sobi · IONS · FDA · European Medicines Agency
Source: finance.yahoo.com
Written by AI from verified reporting.
More stories
- Health & science theguardian.com 0 viewsE coli toxin colibactin flagged to MPs as prime suspect in under-50 bowel cancer rise
- Health & science rarecancernews.com 2 viewsEU approves Rasonque for previously treated metastatic pancreatic cancer
- Health & science medicalxpress.com Caught by @breakwater128 2 viewsFive-Day Antiviral Infusion Safe for Long COVID, ERASE Trial Finds
- Health & science dailycoffeenews.com 2 viewsFDA Pullplug on Methylene Chloride Use, Decaf Ban Fight Continues

